JOIN US for Bonnie Ramsey’s March 28 lecture, ”The Role of Therapeutics Development in Academia”

Presenting the next in our series of Presidential Entrepreneurial Faculty Fellows lectures: “The Role of Therapeutics Development in Academia – Examining the Cystic Fibrosis Research Community as a Model of Success,” Professor Bonnie Ramsey will share lessons learned from shepherding two Cystic Fibrosis drugs successfully through FDA approval — TOBI and Kalydeco.

WHEN: March 28 | 3:00 to 5:00 pm

WHERE: Foege Auditorium (S-060), Foege Hall, UW


FORMAT: 45-min presentation & 15-min Q&A
followed by reception with food and drink

Bonnie Ramsey is a professor of pediatrics holding the Endowed Chair in Cystic Fibrosis Research, the associate program director of the UW General Clinical Research Center and Cystic Fibrosis Research Center at Seattle Children’s Hospital, and co-PI of the UW Institute for Translational Health Sciences Award. Ramsey is a pioneer in developing new treatments to meet the needs of the cystic fibrosis community and is the lead investigator of the clinical trials for TOBI™ (Tobramycin Solution for Inhalation), an inhaled antibiotic treatment for cystic fibrosis.

Together with Arnie Smith, she was involved in commercial development of TOBI™, which is now virtually a standard treatment for CF patients. Ramsey also helped develop the new CF drug, Kalydeco, which recently received FDA approval and is the first CF treatment to target the disease’s genetic cause, not just the symptoms.

The UW Presidential Entrepreneurial Faculty Fellows Lecture Series is designed to inspire UW researchers to pursue commercialization of their innovations by showcasing UW Faculty who have succeeded in translating their research into products and therapies, initiated groundbreaking programs for translation, or established model collaborations with industry.